FDA Clears AI-Powered Ultrasound Tool for Fetal Biometric Measurements
Clarius OB AI reportedly provides estimates of fetal age, weight and growth intervals based on automated fetal biometry measurements available through handheld ultrasound.
The Food and Drug Administration (FDA) has granted 510(k) clearance for Clarius OB AI, an AI-powered handheld ultrasound tool that may bolster access for use of the technology in monitoring fetal wellbeing.
Trained on over 30,000 fetal ultrasound images, Clarius OB AI automates appropriate caliper placement for the calculation of fetal biometry measurements and enables one to add the measurements to patient electronic medical records through the Clarius app, according to Clarius, the developer of Clarius OB AI.
Trained on over 30,000 fetal ultrasound images, the recently FDA-cleared Clarius OB AI tool automates appropriate caliper placement for the calculation of fetal biometry measurements and enables one to add the measurements to patient electronic medical records through the Clarius app. (Image courtesy of Clarius.)
Carolyn L. Gegor, CNN, MS, FACNM, called the Clarius OB AI tool an “excellent teaching modality” that could help reduce the learning curve with OB ultrasound for those who lack experience with ultrasound scanning.
"When I used Clarius OB AI while teaching OB ultrasound to a group of midwives, I was impressed by the accuracy of cursor placement on multiple scans, from crown rump length to biparietal diameter and femur length," noted Gegor, an ARDMS-certified midwife sonographer. "I found that after using the OB AI model, the students were more able to properly measure structures without the assistance of the AI.”
Clarius noted the Clarius OB AI tool is included with Clarius membership and available in the United States and Canada with the Clarius C3 HD3 handheld ultrasound device.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
